Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

NCT01566721

CompletedPhase 3

Sponsor: Hoffmann-La Roche

Conditions: Breast Neoplasms

Interventions: Herceptin

Countries: Albania, Algeria, Argentina, Australia, Bosnia and Herzegovina, Brazil, Bulgaria, Canada

This multicenter, two-cohort, non-randomized, open-label study will evaluate the safety and tolerability of assisted and self-administered SC Herceptin as adjuvant therapy in participants with early HER2-positive breast cancer following tumor excision. Participants will receive Herceptin 600 milligrams (mg) SC every 3 weeks for 18 cycles, either by an assisted administration using a conventional syringe and needle/vial formulation (Cohort A) or with assisted and self-administration using a single-use injection device (SID) in selected participants (Cohort B).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Histologically confirmed early invasive HER2-positive carcinoma of the breast with no evidence of residual, locally recurrent, or metastatic disease and defined as clinical Stage I to IIIC that is eligible for treatment with Herceptin
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Screening left ventricular ejection fraction (LVEF) greater than or equal to (≥) 55%

Exclusion Criteria:

* Previous neoadjuvant or adjuvant breast cancer treatment with an approved or investigational anti-HER2 agent
* History of other malignancy except for curatively treated carcinoma in situ of the cervix, basal cell carcinoma, or curatively treated malignancies (other than breast cancer) where the participant has been disease-free for at least 5 years
* Past history of ductal carcinoma in situ treated with any systemic therapy or with radiation therapy to the ipsilateral breast where invasive cancer subsequently developed
* Metastatic disease
* Inadequate bone marrow, hepatic, or renal function
* Serious cardiac or cardiovascular disease including uncontrolled hypertension or history of hypertensive crisis or hypertensive encephalopathy
* History of severe allergic or immunological reactions, such as difficult-to-control asthma
* Pregnant or lactating women
Locations (437)
  • Tirana, Albania
  • Algiers, Algeria
  • Buenos Aires, Argentina
  • Buenos Aires, Argentina
  • Zárate, Argentina
  • Camperdown, New South Wales, Australia
  • Kogarah, New South Wales, Australia
  • Randwick, New South Wales, Australia
  • Woolloongabba, Queensland, Australia
  • Woodville South, South Australia, Australia
  • Footscray, Victoria, Australia
  • Frankston, Victoria, Australia
  • Malvern, Victoria, Australia
  • Perth, Western Australia, Australia
  • Banja Luka, Bosnia and Herzegovina
  • Sarajevo, Bosnia and Herzegovina
  • Salvador, Estado de Bahia, Brazil
  • Salvador, Estado de Bahia, Brazil
  • Porto Alegre, Rio Grande do Sul, Brazil
  • Jaú, São Paulo, Brazil
  • São Paulo, São Paulo, Brazil
  • São Paulo, São Paulo, Brazil
  • Plovdiv, Bulgaria
  • Sofia, Bulgaria
  • Sofia, Bulgaria
  • Edmonton, Alberta, Canada
  • Vancouver, British Columbia, Canada
  • Moncton, New Brunswick, Canada
  • Oshawa, Ontario, Canada
  • Toronto, Ontario, Canada
  • + 407 more on CT.gov